NEW YORK (GenomeWeb News) - The US Securities and Exchange Commission late last month sued a former Invitrogen official for allegedly trading stock on insider knowledge in 2004, GenomeWeb Daily News has learned.
 
In its complaint, the SEC accuses Harry Yim of sparing himself $80,000 in losses and profiting to the tune of $410,000 by selling shares in Invitrogen soon after the company was informed in a July 7, 2004, meeting that it is in a “crisis” and that “fully 60 percent of Invitrogen’s business is shrinking.”

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.